Decitabine
- Generic Name
- Decitabine
- Brand Names
- Dacogen, Inqovi 5 Tablet Pack
- Drug Type
- Small Molecule
- Chemical Formula
- C8H12N4O4
- CAS Number
- 2353-33-5
- Unique Ingredient Identifier
- 776B62CQ27
- Background
Myelodysplastic syndromes (MDS) are a heterogeneous group of hematopoietic neoplasms with variable underlying etiology and presentation, including neutropenia and thrombocytopenia. Further mutations leading to increased proliferation of cancerous cells can eventually lead to secondary acute myeloid leukemia, which has a poor prognosis. Among treatment option...
- Indication
Decitabine is indicated for the treatment of patients with myelodysplastic syndromes (MDS) including all French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia), as well as for MDS scored ...
- Associated Conditions
- Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome
- Associated Therapies
- -
Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia
- Conditions
- Interventions
- Dietary Supplement: Ascorbic AcidDrug: CarboplatinDrug: DecitabineDrug: CisplatinDrug: CytarabineDrug: DexamethasoneDrug: EtoposideDrug: Gemcitabine HydrochlorideProcedure: Central Venous Cannula InsertionDrug: IfosfamideOther: Laboratory Biomarker AnalysisOther: Placebo AdministrationProcedure: Portacath PlacementOther: Questionnaire AdministrationBiological: RituximabDrug: OxaliplatinProcedure: Biospecimen CollectionProcedure: Core BiopsyProcedure: Bone Marrow AspirationProcedure: Bone Marrow BiopsyProcedure: EchocardiographyProcedure: Positron Emission TomographyProcedure: Magnetic Resonance ImagingProcedure: Computed Tomography
- First Posted Date
- 2018-02-01
- Last Posted Date
- 2024-08-05
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 80
- Registration Number
- NCT03418038
- Locations
- 🇺🇸
Mayo Clinic Health System-Eau Claire Clinic, Eau Claire, Wisconsin, United States
🇺🇸Mayo Clinic Health Systems-Mankato, Mankato, Minnesota, United States
🇺🇸Mayo Clinic Health System-Franciscan Healthcare, La Crosse, Wisconsin, United States
Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome
- Conditions
- Acute Myeloid Leukemia Arising From Previous Myelodysplastic SyndromeRecurrent Chronic Myelomonocytic LeukemiaRefractory Blastic Plasmacytoid Dendritic Cell NeoplasmAcute Myeloid LeukemiaBlastic Plasmacytoid Dendritic Cell NeoplasmChronic Myelomonocytic LeukemiaMixed Phenotype Acute LeukemiaRecurrent Blastic Plasmacytoid Dendritic Cell NeoplasmRecurrent Mixed Phenotype Acute LeukemiaRefractory Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2018-01-19
- Last Posted Date
- 2024-06-20
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 235
- Registration Number
- NCT03404193
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Decitabine,Cytarabine and Arsenic Trioxide for Acute Myeloid Leukemia With p53 Mutations
- Conditions
- Interventions
- First Posted Date
- 2017-12-22
- Last Posted Date
- 2018-01-04
- Lead Sponsor
- Li Junmin
- Target Recruit Count
- 100
- Registration Number
- NCT03381781
- Locations
- 🇨🇳
Shanghai Institute of Hematology, Shanghai, China
🇨🇳Ruijin Hospital North, Shanghai, China
🇨🇳Ruijin Hospital, Shanghai, China
Decitabine and Arsenic Trioxide for Myelodysplastic Syndrome(MDS)
- Conditions
- Interventions
- First Posted Date
- 2017-12-19
- Last Posted Date
- 2023-08-16
- Lead Sponsor
- Li Junmin
- Registration Number
- NCT03377725
- Locations
- 🇨🇳
Ruijin Hospital North, Shanghai, China
🇨🇳Ruijin Hospital, Shanghai, China
🇨🇳Shanghai Institute of Hematology, Shanghai, China
DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2017-12-02
- Last Posted Date
- 2021-10-05
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 8
- Registration Number
- NCT03358719
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
DLAAG in the Treatment of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome With Blast Excess
- Conditions
- Interventions
- First Posted Date
- 2017-11-29
- Last Posted Date
- 2017-11-29
- Lead Sponsor
- Shanghai Tong Ren Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT03356080
- Locations
- 🇨🇳
The center hospital of Shanghai Fengxian District, Shanghai, China
🇨🇳Fujian Medical University Union Hospital, Fuzhou, China
🇨🇳First Affiliated Hospital of Zhengzhou University., Zhengzhou, China
Two Stage Study of Combination of Chemotherapy, SHR-1210 and/or Decitabine for Relapsed/Refractory PMBCLs
- Conditions
- Interventions
- First Posted Date
- 2017-11-17
- Last Posted Date
- 2018-12-03
- Lead Sponsor
- Chinese PLA General Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT03346642
- Locations
- 🇨🇳
Biotherapeutic Department and Pediatrics Department of Chinese PLA General Hospital, Beijing, Beijing, China
🇨🇳Biotherapeutic Department of Chinese PLA General Hospital, Beijing, Beijing, China
Onvansertib in Combination With Either Low-dose Cytarabine or Decitabine in Adult Patients With Acute Myeloid Leukemia (AML)
- Conditions
- Interventions
- First Posted Date
- 2017-10-06
- Last Posted Date
- 2023-02-27
- Lead Sponsor
- Cardiff Oncology
- Target Recruit Count
- 72
- Registration Number
- NCT03303339
- Locations
- 🇺🇸
Virginia Cancer Specialists - Fairfax Office, Fairfax, Virginia, United States
🇺🇸University of Kansas Cancer Center, Westwood, Kansas, United States
🇺🇸University of California Los Angeles, Los Angeles, California, United States
Decitabine Plus Carboplatin in the Treatment of Metastatic TNBC
- First Posted Date
- 2017-09-28
- Last Posted Date
- 2022-04-06
- Lead Sponsor
- Shanghai Jiao Tong University School of Medicine
- Target Recruit Count
- 12
- Registration Number
- NCT03295552
- Locations
- 🇨🇳
Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai, China
Clinical Study of Decitabine and Paclitaxel Combination Therapy
- First Posted Date
- 2017-09-14
- Last Posted Date
- 2018-01-23
- Lead Sponsor
- Dong Wha Pharmaceutical Co. Ltd.
- Target Recruit Count
- 18
- Registration Number
- NCT03282825
- Locations
- 🇰🇷
Yonsei University Health System, Severance Hospital, Seoul, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.